MoonLake Immunotherapeutics announced a $200 million public offering of 9 million Class A shares at $20 each, plus pre-funded warrants, to support the development and commercialization of its drug sonelokimab for inflammatory diseases. The offering, expected to close by June 25, 2026, aims to fund research, pre-commercialization, and general corporate purposes. MoonLake focuses on treatments for conditions like hidradenitis suppurativa and psoriatic arthritis. Underwriters include Leerink Partners and Guggenheim Securities.
Halper Sadeh LLC is investigating whether the sales and merger deals involving AstroNova, Simulations Plus, and Olin Corporation provide fair treatment to their shareholders. The firm suspects insiders may gain financial benefits not available to ord...
Halper Sadeh LLC is investigating whether shareholders of Apogee Therapeutics, Open Lending, Huntsman, and Avanos Medical are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availa...
CEA Industries and YZi Labs have reached a cooperation agreement to strengthen governance at CEA Industries, which manages the world's largest corporate treasury of BNB. The agreement includes appointing three new board members with digital asset exp...
Ethereum recorded the highest net bridge inflows last week with a $64.73 million gain, signaling its role as a preferred liquidity destination. Meanwhile, Arbitrum experienced the largest net outflow of $105.48 million, reflecting active liquidity ro...
Dogecoin dropped 5.54% to $0.079, breaching the $0.08 support level and reaching a three-week low. This decline triggered $7.68 million in liquidations of long positions, causing panic selling and a surge in sell volume. The memecoin's Relative Stren...
